Tamoxifen Citrate

枸橼酸他莫昔芬

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTamoxifen Citrate
Drug Alias NameTamofen枸橼酸它莫西芬三苯甲氨Tamoxifenum柠檬酸三苯氧胺 +[15] 
ClassificationSmall molecules
Mechanisms of ActionEstrogen receptors modulators
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerCNS Embryonal TumorMenopausal symptoms +[38] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date1977/12/30
Country/TerritoryCanadaUnited StatesVietnam +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteRoswell Park Cancer InstituteEuropean Institute Of Oncology +[15] 
Inactive CompaniesUtah State UniversityRadboud University Medical CenterUniversity of Texas Southwestern Medical Center +[21] 
Active IndicationsHyperplasiaHypogonadismHypertension +[22] 
Inactive IndicationsMetastatic breast cancerCNS Embryonal TumorMenopausal symptoms +[16] 

Other Information

ATC CodeL02BA01
Related LinksWikipediaDrugBankKEGG